Detalhe da pesquisa
1.
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Gynecol Oncol
; 161(3): 755-761, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33888336
2.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer
; 31(7): 1031-1036, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33990353
3.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33931498
4.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol
; 156(1): 38-44, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31699415
5.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Int J Mol Sci
; 21(12)2020 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575899
6.
Veliparib: a new therapeutic option in ovarian cancer?
Future Oncol
; 15(17): 1975-1987, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074636
7.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Int J Mol Sci
; 20(9)2019 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31083638
8.
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group.
Int J Gynecol Cancer
; 2022 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314461
9.
A new player in the treatment of HER2-positive tumours.
Lancet Oncol
; 20(6): 748-750, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047805
10.
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
JAMA Oncol
; 9(5): 675-682, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36928279
11.
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1247291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37781174
12.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1357793, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318323
13.
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Nat Commun
; 14(1): 4387, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37474499
14.
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis.
Cancer Treat Rev
; 110: 102458, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063572
15.
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage.
Cancer Treat Rev
; 111: 102467, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265336
16.
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.
Front Oncol
; 12: 880008, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35692798
17.
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
Clin Cancer Res
; 28(13): 2911-2922, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398881
18.
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
Front Oncol
; 11: 689829, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195090
19.
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
Cells
; 10(12)2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34943916
20.
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.
Diagnostics (Basel)
; 10(3)2020 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32156035